Anti-CD38 Antibody and Melphalan Combination for Multiple Myeloma
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for multiple myeloma, including therapies targeting CD38, have limited efficacy and do not provide a cure, leading to relapse and poor prognosis for patients with CD38-expressing tumors.
Innovation Solution
A synergistic combination of an anti-CD38 antibody with melphalan, a nitrogen mustard alkylating agent, which demonstrates enhanced efficacy in reducing bone lysis in multiple myeloma models, offering a promising approach for treating multiple myeloma and other leukemias.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current chemotherapy protocols including CD38-targeting antibodies are used, then complete remission rate is improved, but overall survival remains limited and relapse occurs
Solution Approach 1:
The patent combines anti-CD38 antibodies with melphalan (a nitrogen mustard alkylating agent) to create a synergistic combination therapy. This merging of two different therapeutic mechanisms (antibody-mediated targeting and alkylating chemotherapy) achieves both improved complete remission rates and extended overall survival, resolving the contradiction between initial remission efficacy and long-term survival durability.
2Reliability
If high dose chemotherapy followed by stem cell transplantation is used, then complete remission rate increases, but overall survival is only slightly prolonged
Solution Approach 1:
The patent changes the therapeutic parameters by introducing a combination regimen that integrates antibody therapy with alkylating agent chemotherapy at optimized dosages. This parameter change achieves superior synergistic effects compared to high-dose chemotherapy alone, improving both complete remission rates and overall survival duration without requiring stem cell transplantation.
3Duration of action of stationary object
If maintenance therapy with interferon-alpha is used, then relapse prevention is attempted, but no evidence for cure is obtained
Solution Approach 1:
The patent creates a composite therapeutic approach by combining anti-CD38 antibodies with melphalan, creating a multi-mechanism regimen that addresses both tumor cell killing and immune modulation. This composite therapy provides durable remission with evidence of cure potential, overcoming the limitations of interferon-alpha maintenance therapy.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present disclosure describes a pharmaceutical combination of an anti-CD38 antibody and melphalan.